日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa

骨髓纤维化的定量分析突显了骨髓纤维化的异质性,并增强了组织学评估:来自一项Zinpentraxin alfa II期临床研究的启示

Ryou, Hosuk; Sirinukunwattana, Korsuk; Wood, Ruby; Aberdeen, Alan; Rittscher, Jens; Weinberg, Olga K; Hasserjian, Robert; Pozdnyakova, Olga; Peale, Frank; Higgins, Brian; Lundberg, Pontus; Trunzer, Kerstin; Harrison, Claire N; Royston, Daniel

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial

一项针对既往接受过鲁索替尼治疗或不适合接受鲁索替尼治疗的骨髓纤维化患者的随机、双盲研究:一项 II 期试验的第二阶段,评估了辛喷曲辛α的疗效。

Verstovsek, Srdan; Talpaz, Moshe; Wadleigh, Martha; Isidori, Alessandro; Te Boekhorst, Peter; Savona, Michael R; Bose, Prithviraj; Pozdnyakova, Olga; Mesa, Ruben; El-Galaly, Tarec C; O'Sullivan, Jennifer; Gamel, Katia; Higgins, Brian; Katakam, Sudhakar; Todorov, Boyan; Trunzer, Kerstin; Harrison, Claire N

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial

齐潘曲辛α单药治疗或联合鲁索替尼治疗骨髓纤维化的安全性和有效性:II期临床试验的第一阶段

Verstovsek, Srdan; Foltz, Lynda; Gupta, Vikas; Hasserjian, Robert; Manshouri, Taghi; Mascarenhas, John; Mesa, Ruben; Pozdnyakova, Olga; Ritchie, Ellen; Veletic, Ivo; Gamel, Katia; Hamidi, Habib; Han, Lyrialle; Higgins, Brian; Trunzer, Kerstin; Uguen, Marianne; Wang, Dao; El-Galaly, Tarec Christoffer; Todorov, Boyan; Gotlib, Jason

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

来自 ALUR III 期研究的最终疗效和安全性数据,以及阿来替尼与化疗在克唑替尼预处理的 ALK 阳性非小细胞肺癌患者中的探索性分子谱分析

Wolf, J; Helland, Å; Oh, I-J; Migliorino, M R; Dziadziuszko, R; Wrona, A; de Castro, J; Mazieres, J; Griesinger, F; Chlistalla, M; Cardona, A; Ruf, T; Trunzer, K; Smoljanovic, V; Novello, S

Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

TAIL研究的主要结果:一项针对既往接受过治疗的晚期非小细胞肺癌患者的阿特珠单抗单药治疗的全球单臂安全性研究

Ardizzoni, Andrea; Azevedo, Sergio; Rubio-Viqueira, Belen; Rodríguez-Abreu, Delvys; Alatorre-Alexander, Jorge; Smit, Hans J M; Yu, Jinming; Syrigos, Konstantinos; Trunzer, Kerstin; Patel, Hina; Tolson, Jonathan; Cardona, Andres; Perez-Moreno, Pablo D; Newsom-Davis, Tom

Benzalkonium Chloride Induces a VBNC State in Listeria monocytogenes

苯扎氯铵诱导单核细胞增生李斯特菌进入VBNC状态

Noll, Matthias; Trunzer, Katharina; Vondran, Antje; Vincze, Szilvia; Dieckmann, Ralf; Al Dahouk, Sascha; Gold, Carolin

A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens

一项非干预性、多国研究,旨在评估肺癌细胞学和组织学标本中PD-L1的表达。

Bubendorf, Lukas; Conde, Esther; Cappuzzo, Federico; Langfort, Renata; Schildhaus, Hans-Ulrich; Votruba, Jiří; Concha-López, Ángel; Esteban-Rodriguez, Isabel; Feng, Janine; Devenport, Jenny; Boyiddle, Christine; Morris, Stefanie; Trunzer, Kerstin; Kerr, Keith M

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

接受苯丁酸氮芥联合奥妥珠单抗或利妥昔单抗治疗的合并症慢性淋巴细胞白血病患者中微小残留病灶的预后价值

Langerak, Anton W; Ritgen, Matthias; Goede, Valentin; Robrecht, Sandra; Bahlo, Jasmin; Fischer, Kirsten; Steurer, Michael; Trněný, Marek; Mulligan, Stephen P; Mey, Ulrich J M; Trunzer, Kerstin; Fingerle-Rowson, Günter; Humphrey, Kathryn; Stilgenbauer, Stephan; Böttcher, Sebastian; Brüggemann, Monika; Hallek, Michael; Kneba, Michael; van Dongen, Jacques J M

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

对接受维莫非尼治疗的黑色素瘤患者的皮肤病事件进行分析

Lacouture, Mario E; Duvic, Madeleine; Hauschild, Axel; Prieto, Victor G; Robert, Caroline; Schadendorf, Dirk; Kim, Caroline C; McCormack, Christopher J; Myskowski, Patricia L; Spleiss, Olivia; Trunzer, Kerstin; Su, Fei; Nelson, Betty; Nolop, Keith B; Grippo, Joseph F; Lee, Richard J; Klimek, Matthew J; Troy, James L; Joe, Andrew K

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

接受 BRAF 抑制剂治疗的患者皮肤鳞状细胞癌中的 RAS 突变

Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S; Kong, Xiangju; Koya, Richard C; Flaherty, Keith T; Chapman, Paul B; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lídia; Otte, Nicholas J; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B; Lee, Richard J; Joe, Andrew K; Troy, James L; Gonzalez, Rene; Hutson, Thomas E; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J; McArthur, Grant A; Sosman, Jeffrey A; Lo, Roger S; Ribas, Antoni; Marais, Richard